JP2020515240A - 新規乳酸菌およびその用途 - Google Patents
新規乳酸菌およびその用途 Download PDFInfo
- Publication number
- JP2020515240A JP2020515240A JP2019541313A JP2019541313A JP2020515240A JP 2020515240 A JP2020515240 A JP 2020515240A JP 2019541313 A JP2019541313 A JP 2019541313A JP 2019541313 A JP2019541313 A JP 2019541313A JP 2020515240 A JP2020515240 A JP 2020515240A
- Authority
- JP
- Japan
- Prior art keywords
- lactobacillus plantarum
- bifidobacterium longum
- kccm11961p
- kccm11962p
- allergic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 title description 176
- 239000004310 lactic acid Substances 0.000 title description 88
- 235000014655 lactic acid Nutrition 0.000 title description 88
- 241000894006 Bacteria Species 0.000 title description 87
- 208000026935 allergic disease Diseases 0.000 claims abstract description 51
- 208000006673 asthma Diseases 0.000 claims abstract description 51
- 206010039083 rhinitis Diseases 0.000 claims abstract description 22
- 241000186660 Lactobacillus Species 0.000 claims abstract description 11
- 229940039696 lactobacillus Drugs 0.000 claims abstract description 11
- 206010003645 Atopy Diseases 0.000 claims abstract description 5
- 239000000463 material Substances 0.000 claims abstract description 5
- 241001608472 Bifidobacterium longum Species 0.000 claims description 144
- 229940009291 bifidobacterium longum Drugs 0.000 claims description 143
- 240000006024 Lactobacillus plantarum Species 0.000 claims description 132
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims description 132
- 229940072205 lactobacillus plantarum Drugs 0.000 claims description 132
- 239000000203 mixture Substances 0.000 claims description 83
- 239000008194 pharmaceutical composition Substances 0.000 claims description 36
- 238000011282 treatment Methods 0.000 claims description 30
- 235000013305 food Nutrition 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 20
- 208000027866 inflammatory disease Diseases 0.000 claims description 19
- 108020004465 16S ribosomal RNA Proteins 0.000 claims description 17
- 230000002265 prevention Effects 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 15
- 229940079593 drug Drugs 0.000 claims description 13
- 239000000284 extract Substances 0.000 claims description 13
- 208000026278 immune system disease Diseases 0.000 claims description 11
- 239000002773 nucleotide Substances 0.000 claims description 11
- 125000003729 nucleotide group Chemical group 0.000 claims description 11
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 10
- 229910052799 carbon Inorganic materials 0.000 claims description 10
- 229920001661 Chitosan Polymers 0.000 claims description 9
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 8
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 8
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 8
- 229960004793 sucrose Drugs 0.000 claims description 8
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 7
- 229920001202 Inulin Polymers 0.000 claims description 7
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 7
- 229940029339 inulin Drugs 0.000 claims description 7
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 6
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 6
- 229930006000 Sucrose Natural products 0.000 claims description 6
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 6
- 229940045110 chitosan Drugs 0.000 claims description 6
- 229940040387 citrus pectin Drugs 0.000 claims description 6
- 239000009194 citrus pectin Substances 0.000 claims description 6
- 229960001031 glucose Drugs 0.000 claims description 6
- 229960002920 sorbitol Drugs 0.000 claims description 6
- 239000005720 sucrose Substances 0.000 claims description 6
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 5
- 201000008937 atopic dermatitis Diseases 0.000 claims description 5
- 206010009887 colitis Diseases 0.000 claims description 5
- 239000008101 lactose Substances 0.000 claims description 5
- 235000010355 mannitol Nutrition 0.000 claims description 5
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 claims description 4
- PLXMOAALOJOTIY-FPTXNFDTSA-N Aesculin Natural products OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1Oc2cc3C=CC(=O)Oc3cc2O PLXMOAALOJOTIY-FPTXNFDTSA-N 0.000 claims description 4
- 206010002199 Anaphylactic shock Diseases 0.000 claims description 4
- WNBCMONIPIJTSB-BGNCJLHMSA-N Cichoriin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1)c1c(O)cc2c(OC(=O)C=C2)c1 WNBCMONIPIJTSB-BGNCJLHMSA-N 0.000 claims description 4
- SRBFZHDQGSBBOR-SOOFDHNKSA-N D-ribopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@@H]1O SRBFZHDQGSBBOR-SOOFDHNKSA-N 0.000 claims description 4
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 4
- NGFMICBWJRZIBI-JZRPKSSGSA-N Salicin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O1)c1c(CO)cccc1 NGFMICBWJRZIBI-JZRPKSSGSA-N 0.000 claims description 4
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 claims description 4
- 208000024780 Urticaria Diseases 0.000 claims description 4
- PYMYPHUHKUWMLA-LMVFSUKVSA-N aldehydo-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims description 4
- NGFMICBWJRZIBI-UHFFFAOYSA-N alpha-salicin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UHFFFAOYSA-N 0.000 claims description 4
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 4
- XHCADAYNFIFUHF-TVKJYDDYSA-N esculin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC2=C1OC(=O)C=C2 XHCADAYNFIFUHF-TVKJYDDYSA-N 0.000 claims description 4
- 229940093496 esculin Drugs 0.000 claims description 4
- AWRMZKLXZLNBBK-UHFFFAOYSA-N esculin Natural products OC1OC(COc2cc3C=CC(=O)Oc3cc2O)C(O)C(O)C1O AWRMZKLXZLNBBK-UHFFFAOYSA-N 0.000 claims description 4
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 claims description 4
- 229960002160 maltose Drugs 0.000 claims description 4
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 claims description 4
- NGFMICBWJRZIBI-UJPOAAIJSA-N salicin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UJPOAAIJSA-N 0.000 claims description 4
- 229940120668 salicin Drugs 0.000 claims description 4
- 239000000600 sorbitol Substances 0.000 claims description 4
- 235000010356 sorbitol Nutrition 0.000 claims description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 3
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- 208000002205 allergic conjunctivitis Diseases 0.000 claims description 3
- 208000003455 anaphylaxis Diseases 0.000 claims description 3
- 208000024998 atopic conjunctivitis Diseases 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 229960001855 mannitol Drugs 0.000 claims description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 2
- XUCIJNAGGSZNQT-JHSLDZJXSA-N (R)-amygdalin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@@H](C#N)C=2C=CC=CC=2)O1 XUCIJNAGGSZNQT-JHSLDZJXSA-N 0.000 claims description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 claims description 2
- RFSUNEUAIZKAJO-VRPWFDPXSA-N D-Fructose Natural products OC[C@H]1OC(O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-VRPWFDPXSA-N 0.000 claims description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 claims description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 claims description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 2
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 claims description 2
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 claims description 2
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 claims description 2
- DKXNBNKWCZZMJT-UHFFFAOYSA-N O4-alpha-D-Mannopyranosyl-D-mannose Natural products O=CC(O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O DKXNBNKWCZZMJT-UHFFFAOYSA-N 0.000 claims description 2
- AYRXSINWFIIFAE-UHFFFAOYSA-N O6-alpha-D-Galactopyranosyl-D-galactose Natural products OCC1OC(OCC(O)C(O)C(O)C(O)C=O)C(O)C(O)C1O AYRXSINWFIIFAE-UHFFFAOYSA-N 0.000 claims description 2
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 claims description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 2
- 229940089837 amygdalin Drugs 0.000 claims description 2
- YZLOSXFCSIDECK-UHFFFAOYSA-N amygdalin Natural products OCC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC(C#N)c3ccccc3 YZLOSXFCSIDECK-UHFFFAOYSA-N 0.000 claims description 2
- 229960000271 arbutin Drugs 0.000 claims description 2
- DLRVVLDZNNYCBX-ZZFZYMBESA-N beta-melibiose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)O1 DLRVVLDZNNYCBX-ZZFZYMBESA-N 0.000 claims description 2
- YGHHWSRCTPQFFC-UHFFFAOYSA-N eucalyptosin A Natural products OC1C(O)C(O)C(CO)OC1OC1C(OC(C#N)C=2C=CC=CC=2)OC(CO)C(O)C1O YGHHWSRCTPQFFC-UHFFFAOYSA-N 0.000 claims description 2
- 229960002413 ferric citrate Drugs 0.000 claims description 2
- DLRVVLDZNNYCBX-CQUJWQHSSA-N gentiobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-CQUJWQHSSA-N 0.000 claims description 2
- 229940050410 gluconate Drugs 0.000 claims description 2
- NPFOYSMITVOQOS-UHFFFAOYSA-K iron(III) citrate Chemical compound [Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NPFOYSMITVOQOS-UHFFFAOYSA-K 0.000 claims description 2
- 229950006780 n-acetylglucosamine Drugs 0.000 claims description 2
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 claims description 2
- 206010061557 Allergic otitis media Diseases 0.000 claims 2
- 201000010435 allergic urticaria Diseases 0.000 claims 2
- RULSWEULPANCDV-PIXUTMIVSA-N turanose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](C(=O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RULSWEULPANCDV-PIXUTMIVSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 23
- 230000028709 inflammatory response Effects 0.000 abstract description 17
- 206010061218 Inflammation Diseases 0.000 abstract description 16
- 230000004054 inflammatory process Effects 0.000 abstract description 16
- 235000013376 functional food Nutrition 0.000 abstract description 12
- 230000002519 immonomodulatory effect Effects 0.000 abstract description 9
- 241000186000 Bifidobacterium Species 0.000 abstract description 8
- 210000003608 fece Anatomy 0.000 abstract description 6
- 235000021109 kimchi Nutrition 0.000 abstract description 6
- 230000001629 suppression Effects 0.000 abstract description 6
- 235000010149 Brassica rapa subsp chinensis Nutrition 0.000 abstract description 5
- 235000000536 Brassica rapa subsp pekinensis Nutrition 0.000 abstract description 5
- 241000499436 Brassica rapa subsp. pekinensis Species 0.000 abstract description 5
- 230000001766 physiological effect Effects 0.000 abstract description 4
- 238000010586 diagram Methods 0.000 abstract 1
- 230000003832 immune regulation Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 39
- 206010039085 Rhinitis allergic Diseases 0.000 description 37
- 201000010105 allergic rhinitis Diseases 0.000 description 37
- 201000010099 disease Diseases 0.000 description 32
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 32
- 230000006698 induction Effects 0.000 description 29
- 102000000743 Interleukin-5 Human genes 0.000 description 28
- 108010002616 Interleukin-5 Proteins 0.000 description 28
- 230000003247 decreasing effect Effects 0.000 description 28
- 201000009961 allergic asthma Diseases 0.000 description 27
- 238000010171 animal model Methods 0.000 description 26
- 238000012360 testing method Methods 0.000 description 25
- 241000699666 Mus <mouse, genus> Species 0.000 description 24
- 102000003814 Interleukin-10 Human genes 0.000 description 23
- 108090000174 Interleukin-10 Proteins 0.000 description 23
- 210000001744 T-lymphocyte Anatomy 0.000 description 22
- 210000004241 Th2 cell Anatomy 0.000 description 21
- 230000024245 cell differentiation Effects 0.000 description 21
- 210000003289 regulatory T cell Anatomy 0.000 description 21
- 238000004519 manufacturing process Methods 0.000 description 20
- 102000004127 Cytokines Human genes 0.000 description 19
- 108090000695 Cytokines Proteins 0.000 description 19
- 239000012530 fluid Substances 0.000 description 18
- 102000004388 Interleukin-4 Human genes 0.000 description 17
- 108090000978 Interleukin-4 Proteins 0.000 description 17
- 239000000126 substance Substances 0.000 description 17
- 108010058846 Ovalbumin Proteins 0.000 description 16
- 239000002609 medium Substances 0.000 description 16
- 229940092253 ovalbumin Drugs 0.000 description 16
- 210000001519 tissue Anatomy 0.000 description 15
- 206010020751 Hypersensitivity Diseases 0.000 description 14
- 239000000047 product Substances 0.000 description 14
- 230000004069 differentiation Effects 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 13
- 230000036541 health Effects 0.000 description 13
- 210000004072 lung Anatomy 0.000 description 13
- 210000002966 serum Anatomy 0.000 description 12
- 208000024891 symptom Diseases 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 11
- 230000005764 inhibitory process Effects 0.000 description 11
- 244000005700 microbiome Species 0.000 description 11
- 210000003928 nasal cavity Anatomy 0.000 description 11
- 101000819111 Homo sapiens Trans-acting T-cell-specific transcription factor GATA-3 Proteins 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 10
- 239000012980 RPMI-1640 medium Substances 0.000 description 10
- 102100021386 Trans-acting T-cell-specific transcription factor GATA-3 Human genes 0.000 description 10
- 208000010216 atopic IgE responsiveness Diseases 0.000 description 10
- 239000000546 pharmaceutical excipient Substances 0.000 description 10
- 239000002953 phosphate buffered saline Substances 0.000 description 10
- 210000000447 Th1 cell Anatomy 0.000 description 9
- 210000000068 Th17 cell Anatomy 0.000 description 9
- 210000002540 macrophage Anatomy 0.000 description 9
- 235000013406 prebiotics Nutrition 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- 102000013462 Interleukin-12 Human genes 0.000 description 8
- 108010065805 Interleukin-12 Proteins 0.000 description 8
- 238000011529 RT qPCR Methods 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 102000036639 antigens Human genes 0.000 description 8
- 108091007433 antigens Proteins 0.000 description 8
- 210000004443 dendritic cell Anatomy 0.000 description 8
- 210000003630 histaminocyte Anatomy 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 238000002156 mixing Methods 0.000 description 8
- 230000003449 preventive effect Effects 0.000 description 8
- 241000894007 species Species 0.000 description 8
- 229920001817 Agar Polymers 0.000 description 7
- 239000008272 agar Substances 0.000 description 7
- 239000000427 antigen Substances 0.000 description 7
- 238000009826 distribution Methods 0.000 description 7
- 239000002158 endotoxin Substances 0.000 description 7
- 230000000968 intestinal effect Effects 0.000 description 7
- 210000002429 large intestine Anatomy 0.000 description 7
- 229920006008 lipopolysaccharide Polymers 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 6
- 108010057466 NF-kappa B Proteins 0.000 description 6
- 102000003945 NF-kappa B Human genes 0.000 description 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 6
- 102100040247 Tumor necrosis factor Human genes 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 239000013566 allergen Substances 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 210000003979 eosinophil Anatomy 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 235000013355 food flavoring agent Nutrition 0.000 description 6
- 239000008187 granular material Substances 0.000 description 6
- 239000000411 inducer Substances 0.000 description 6
- 230000001939 inductive effect Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 5
- 238000008157 ELISA kit Methods 0.000 description 5
- 206010028741 Nasal inflammation Diseases 0.000 description 5
- 241000209140 Triticum Species 0.000 description 5
- 235000021307 Triticum Nutrition 0.000 description 5
- 230000007815 allergy Effects 0.000 description 5
- 239000011230 binding agent Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 230000000813 microbial effect Effects 0.000 description 5
- 239000006187 pill Substances 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 102100037850 Interferon gamma Human genes 0.000 description 4
- 108010074328 Interferon-gamma Proteins 0.000 description 4
- 108050003558 Interleukin-17 Proteins 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 210000000683 abdominal cavity Anatomy 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 239000008186 active pharmaceutical agent Substances 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- -1 cysteinyl leukotrienes Chemical class 0.000 description 4
- 229940084954 dexamethasone 1 mg Drugs 0.000 description 4
- 210000002919 epithelial cell Anatomy 0.000 description 4
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 4
- 235000013373 food additive Nutrition 0.000 description 4
- 239000002778 food additive Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 238000007790 scraping Methods 0.000 description 4
- 206010041232 sneezing Diseases 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- 235000012222 talc Nutrition 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 101000713602 Homo sapiens T-box transcription factor TBX21 Proteins 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- 102000004889 Interleukin-6 Human genes 0.000 description 3
- 240000001046 Lactobacillus acidophilus Species 0.000 description 3
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 241000192142 Proteobacteria Species 0.000 description 3
- 108091008778 RORγ2 Proteins 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 102100036840 T-box transcription factor TBX21 Human genes 0.000 description 3
- 206010054000 Type II hypersensitivity Diseases 0.000 description 3
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 3
- 230000000172 allergic effect Effects 0.000 description 3
- 208000030961 allergic reaction Diseases 0.000 description 3
- 230000001088 anti-asthma Effects 0.000 description 3
- 239000000924 antiasthmatic agent Substances 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 210000003651 basophil Anatomy 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 235000014121 butter Nutrition 0.000 description 3
- 235000013339 cereals Nutrition 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 235000013365 dairy product Nutrition 0.000 description 3
- 238000000151 deposition Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 3
- 229960003957 dexamethasone Drugs 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 239000007884 disintegrant Substances 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000010419 fine particle Substances 0.000 description 3
- 235000013312 flour Nutrition 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 229960001340 histamine Drugs 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000008026 type II hypersensitivity Effects 0.000 description 3
- 208000025883 type III hypersensitivity disease Diseases 0.000 description 3
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 3
- 241001156739 Actinobacteria <phylum> Species 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 241000606125 Bacteroides Species 0.000 description 2
- 241001107116 Castanospermum australe Species 0.000 description 2
- 241000272201 Columbiformes Species 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 240000005979 Hordeum vulgare Species 0.000 description 2
- 235000007340 Hordeum vulgare Nutrition 0.000 description 2
- 102000003816 Interleukin-13 Human genes 0.000 description 2
- 108090000176 Interleukin-13 Proteins 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 102000009571 Macrophage Inflammatory Proteins Human genes 0.000 description 2
- 108010009474 Macrophage Inflammatory Proteins Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 206010033078 Otitis media Diseases 0.000 description 2
- 235000003434 Sesamum indicum Nutrition 0.000 description 2
- 244000040738 Sesamum orientale Species 0.000 description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 102100035100 Transcription factor p65 Human genes 0.000 description 2
- 206010053614 Type III immune complex mediated reaction Diseases 0.000 description 2
- 206010047642 Vitiligo Diseases 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 239000000043 antiallergic agent Substances 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 239000002543 antimycotic Substances 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 235000021279 black bean Nutrition 0.000 description 2
- 235000007215 black sesame Nutrition 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- 235000021329 brown rice Nutrition 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 238000010562 histological examination Methods 0.000 description 2
- 230000008105 immune reaction Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 229940041476 lactose 100 mg Drugs 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 235000012149 noodles Nutrition 0.000 description 2
- 210000001331 nose Anatomy 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 229960003415 propylparaben Drugs 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 201000009890 sinusitis Diseases 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 229940071127 thioglycolate Drugs 0.000 description 2
- CWERGRDVMFNCDR-UHFFFAOYSA-M thioglycolate(1-) Chemical compound [O-]C(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-M 0.000 description 2
- 235000015192 vegetable juice Nutrition 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 208000026872 Addison Disease Diseases 0.000 description 1
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
- 206010027654 Allergic conditions Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 108700029181 Bacteria lipase activator Proteins 0.000 description 1
- 241000605059 Bacteroidetes Species 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- 241000186018 Bifidobacterium adolescentis Species 0.000 description 1
- 241000131482 Bifidobacterium sp. Species 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 102100035882 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 241000218645 Cedrus Species 0.000 description 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 235000011511 Diospyros Nutrition 0.000 description 1
- 244000236655 Diospyros kaki Species 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 206010051841 Exposure to allergen Diseases 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 240000008397 Ganoderma lucidum Species 0.000 description 1
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 240000004670 Glycyrrhiza echinata Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 238000003794 Gram staining Methods 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 102000000543 Histamine Receptors Human genes 0.000 description 1
- 108010002059 Histamine Receptors Proteins 0.000 description 1
- 229940122236 Histamine receptor antagonist Drugs 0.000 description 1
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 206010065390 Inflammatory pain Diseases 0.000 description 1
- 102100022338 Integrin alpha-M Human genes 0.000 description 1
- 241000186610 Lactobacillus sp. Species 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 208000027530 Meniere disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
- 101000863881 Mus musculus Sialic acid-binding Ig-like lectin 5 Proteins 0.000 description 1
- 206010029400 Nicotinic acid deficiency Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- QACUPNAKIPYZAW-RMQWDSPGSA-N O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O QACUPNAKIPYZAW-RMQWDSPGSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 208000002141 Pellagra Diseases 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 201000002661 Spondylitis Diseases 0.000 description 1
- 201000009594 Systemic Scleroderma Diseases 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 206010045240 Type I hypersensitivity Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- 201000008100 Vaginitis Diseases 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000000538 analytical sample Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 235000015197 apple juice Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 235000015190 carrot juice Nutrition 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 239000007931 coated granule Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 238000000748 compression moulding Methods 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000012495 crackers Nutrition 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- HBEDSQVIWPRPAY-UHFFFAOYSA-N dihydro-benzofuran Natural products C1=CC=C2OCCC2=C1 HBEDSQVIWPRPAY-UHFFFAOYSA-N 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 235000021107 fermented food Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 210000003736 gastrointestinal content Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000012812 general test Methods 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 235000019674 grape juice Nutrition 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- OFWOMCSHJWTBGF-UHFFFAOYSA-N name was omitted Natural products CC(C)=CCCC(O)(CO)C=C OFWOMCSHJWTBGF-UHFFFAOYSA-N 0.000 description 1
- 235000019462 natural additive Nutrition 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 208000008423 pleurisy Diseases 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- GRLPQNLYRHEGIJ-UHFFFAOYSA-J potassium aluminium sulfate Chemical compound [Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O GRLPQNLYRHEGIJ-UHFFFAOYSA-J 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 235000020712 soy bean extract Nutrition 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 235000015193 tomato juice Nutrition 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 230000005951 type IV hypersensitivity Effects 0.000 description 1
- 208000000143 urethritis Diseases 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A21—BAKING; EDIBLE DOUGHS
- A21D—TREATMENT, e.g. PRESERVATION, OF FLOUR OR DOUGH, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS; PRESERVATION THEREOF
- A21D8/00—Methods for preparing or baking dough
- A21D8/02—Methods for preparing dough; Treating dough prior to baking
- A21D8/04—Methods for preparing dough; Treating dough prior to baking treating dough with microorganisms or enzymes
-
- A—HUMAN NECESSITIES
- A21—BAKING; EDIBLE DOUGHS
- A21D—TREATMENT, e.g. PRESERVATION, OF FLOUR OR DOUGH, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS; PRESERVATION THEREOF
- A21D8/00—Methods for preparing or baking dough
- A21D8/02—Methods for preparing dough; Treating dough prior to baking
- A21D8/04—Methods for preparing dough; Treating dough prior to baking treating dough with microorganisms or enzymes
- A21D8/045—Methods for preparing dough; Treating dough prior to baking treating dough with microorganisms or enzymes with a leaven or a composition containing acidifying bacteria
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
- A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/127—Fermented milk preparations; Treatment using microorganisms or enzymes using microorganisms of the genus lactobacteriaceae and other microorganisms or enzymes, e.g. kefir, koumiss
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G4/00—Chewing gum
- A23G4/06—Chewing gum characterised by the composition containing organic or inorganic compounds
- A23G4/12—Chewing gum characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/02—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation containing fruit or vegetable juices
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
- A23L7/10—Cereal-derived products
- A23L7/104—Fermentation of farinaceous cereal or cereal material; Addition of enzymes or microorganisms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/732—Pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/733—Fructosans, e.g. inulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/169—Plantarum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/533—Longum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K2035/11—Medicinal preparations comprising living procariotic cells
- A61K2035/115—Probiotics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
- C12R2001/25—Lactobacillus plantarum
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Food Science & Technology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Polymers & Plastics (AREA)
- Biotechnology (AREA)
- Nutrition Science (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
前記食品の種類に特に制限はない。本発明の抽出物を添加できる食品の例としては飲料、ガム、ビタミン複合剤、ドリンク剤などが挙げられ、通常の意味での食品組成物、特に健康機能食品を全て含む。
*enzyme−linked immunosorbent assay(ELISA):IL−10、IL−5、IL−6、IL−4、IgEなど
*FACS(Fluorescence−activated cell sorting):T細胞(Th1:CD4+/IFN−γ+;Th2:CD4+/IL−4+;Treg:CD4+/FOXp3+;Th17:CD4+/IL−17+)分布、好酸球(CD11b+、Siglec−F+)分布
Bifidobacterium longum IM55培養物 20mg
乳糖 100mg
タルク 10mg
前記成分を混合し、気密布に充填して散剤を製造した。
Bifidobacterium longum IM55培養物 10mg
トウモロコシデンプン 100mg
乳糖 100mg
ステアリン酸マグネシウム 2mg
前記成分を混合した後、通常の錠剤の製造方法により打錠して錠剤を製造した。
Bifidobacterium longum IM55培養物 10mg
結晶性セルロース 3mg
乳糖 15mg
ステアリン酸マグネシウム 0.2mg
前記成分を混合した後、通常のカプセル剤の製造方法によりゼラチンカプセルに充填してカプセル剤を製造した。
Bifidobacterium longum IM55培養物 10mg
乳糖 150mg
グリセリン 100mg
キシリトール 50mg
前記成分を混合した後、通常の方法により1丸剤当たりに4gになるように製造した。
Bifidobacterium longum IM55培養物 15mg
大豆抽出物 50mg
ブドウ糖 200mg
デンプン 600mg
前記成分を混合した後、30%エタノール100mgを添加して摂氏60℃で乾燥して顆粒を形成した後に布に充填した。
Bifidobacterium longum IM55培養物 10mg
メタ重亜硫酸ナトリウム 3.0mg
メチルパラベン 0.8mg
プロピルパラベン 0.1mg
注射用滅菌蒸留水 適量
前記成分を混合した後、この中で2mlをアンプルに充填し滅菌して注射剤を製造した。
小麦粉100重量部にBifidobacterium longum IM55培養物0.5重量部を小麦粉に添加し、該混合物を用いてパン、ケーキ、クッキー、クラッカーおよび麺類を製造した。
牛乳100重量部にBifidobacterium longum IM55培養物0.5重量部を牛乳に添加し、該牛乳を用いてバターおよびアイスクリームのような様々な乳製品を製造した。
玄米、麦、もち米、鳩麦を公知の方法によりアルファ化して乾燥させたものを焙煎した後、粉砕機で粒度60メッシュの粉末に製造した。
黒豆、黒ゴマ、エゴマも公知の方法により蒸して乾燥させたものを焙煎した後、粉砕機で粒度60メッシュの粉末に製造した。
前記で製造した穀物類、種実類およびBifidobacterium longum IM55培養物を次の比率で配合して製造した。
穀物類(玄米30重量部、鳩麦17重量部、麦20重量部)、
種実類(エゴマ7重量部、黒豆8重量部、黒ゴマ7重量部)、
Bifidobacterium longum IM55培養物(1重量部)、
霊芝(0.5重量部)、
地黄(0.5重量部)
異性化糖(0.5g)、オリゴ糖(4g)、砂糖(2g)、食塩(0.5g)、水(77g)のような副材料とBifidobacterium longum IM55培養物1gを均質に配合して瞬間殺菌をした後、それをガラス瓶、ペットボトルなどの小さい包装容器に包装して製造した。
Bifidobacterium longum IM55培養物2gをトマトまたはニンジンのジュース1,000mlに加えて野菜ジュースを製造した。
Bifidobacterium longum IM55培養物1gをリンゴまたはブドウのジュース1,000mlに加えて果汁を製造した。
受託番号:KCCM11961P
受託日:2017年01月20日
寄託機関名:韓国微生物保存センター(国外)
受託番号:KCCM11962P
受託日:2017年01月20日
Claims (22)
- ビフィドバクテリウム・ロンガムIM55(Bifidobacterium longum IM55)KCCM11961P。
- ラクトバチルス・プランタルムIM76(Lactobacillus plantarum IM76)KCCM11962P。
- 前記ビフィドバクテリウム・ロンガムIM55(Bifidobacterium longum IM55)KCCM11961Pは、配列番号1の16S rDNA塩基配列を含むことを特徴とする、請求項1に記載のビフィドバクテリウム・ロンガムIM55(Bifidobacterium longum IM55)KCCM11961P。
- 前記ビフィドバクテリウム・ロンガムIM55(Bifidobacterium longum IM55)KCCM11961Pは、炭素源としてD−グルコース、D−マンニトール、D−ラクトース、D−スクロース、D−マルトース、サリシン、D−キシロース、L−アラビノース、エスクリンフェリックシトラート(esculin ferric citrate)、D−ラフィノースおよびD−ソルビトールを用いることを特徴とする、請求項1に記載のビフィドバクテリウム・ロンガムIM55(Bifidobacterium longum IM55)KCCM11961P。
- 前記ラクトバチルス・プランタルムIM76(Lactobacillus plantarum IM76)KCCM11962Pは、配列番号2の16S rDNA塩基配列を含むことを特徴とする、請求項2に記載のラクトバチルス・プランタルムIM76(Lactobacillus plantarum IM76)KCCM11962P。
- 前記ラクトバチルス・プランタルムIM76(Lactobacillus plantarum IM76)KCCM11962Pは、炭素源としてL−アラビノース、D−リボース、D−ガラクトース、D−グルコース、D−フルクトース、D−マンノース、マンニトール、ソルビトール、N−アセチル−グルコサミン、アミグダリン、アルブチン、エスクリン(esculin)、サリシン、セロビオース、マルトース、ラクトース、メリビオース、スクロース、トレハロース、ラフィノース、ゲンチオビオース、D−ツラノースおよびグルコネートを用いることを特徴とする、請求項2に記載のラクトバチルス・プランタルムIM76(Lactobacillus plantarum IM76)KCCM11962P。
- ビフィドバクテリウム・ロンガムIM55(Bifidobacterium longum IM55)KCCM11961P、ラクトバチルス・プランタルムIM76(Lactobacillus plantarum IM76)KCCM11962Pまたはその混合物を含む、アレルギー疾患の予防または治療用薬学組成物。
- 前記ビフィドバクテリウム・ロンガムIM55(Bifidobacterium longum IM55)KCCM11961Pは、その生菌体、その死菌体、その培養物、その破砕物またはその抽出物であることを特徴とする、請求項7に記載の薬学組成物。
- 前記ラクトバチルス・プランタルムIM76(Lactobacillus plantarum IM76)KCCM11962Pは、その生菌体、その死菌体、その培養物、その破砕物またはその抽出物であることを特徴とする、請求項7に記載の薬学組成物。
- 前記アレルギー疾患は、鼻炎、アトピー、喘息、アトピー性皮膚炎、アレルギー性結膜炎、アレルギー性中耳炎、じんましんおよびアナフィラキシーショックを含む群より選択されたいずれか一つ以上であることを特徴とする、請求項7に記載の薬学組成物。
- 前記薬学組成物は、キトサン(chitosan)、イヌリン(inulin)および柑橘ペクチン(citrus pectin)を含む群より選択される1種以上をさらに含むことを特徴とする、請求項7に記載の薬学組成物。
- ビフィドバクテリウム・ロンガムIM55(Bifidobacterium longum IM55)KCCM11961P、ラクトバチルス・プランタルムIM76(Lactobacillus plantarum IM76)KCCM11962Pまたはその混合物を含む、アレルギー疾患の予防または改善用食品組成物。
- 前記ビフィドバクテリウム・ロンガムIM55(Bifidobacterium longum IM55)KCCM11961Pは、その生菌体、その死菌体、その培養物、その破砕物またはその抽出物であることを特徴とする、請求項12に記載の食品組成物。
- 前記ラクトバチルス・プランタルムIM76(Lactobacillus plantarum IM76)KCCM11962Pは、その生菌体、その死菌体、その培養物、その破砕物またはその抽出物であることを特徴とする、請求項12に記載の食品組成物。
- 前記アレルギー疾患は、鼻炎、アトピー、喘息、アトピー性皮膚炎、アレルギー性結膜炎、アレルギー性中耳炎、じんましんおよびアナフィラキシーショックを含む群より選択されたいずれか一つ以上であることを特徴とする、請求項12に記載の食品組成物。
- 前記薬学組成物は、キトサン(chitosan)、イヌリン(inulin)および柑橘ペクチン(citrus pectin)を含む群より選択される1種以上をさらに含むことを特徴とする、請求項12に記載の食品組成物。
- ビフィドバクテリウム・ロンガムIM55(Bifidobacterium longum IM55)KCCM11961P、ラクトバチルス・プランタルムIM76(Lactobacillus plantarum IM76)KCCM11962Pまたはその混合物を含む、免疫疾患または炎症疾患の予防または治療用薬学組成物。
- 前記炎症疾患は大腸炎である、請求項17に記載の免疫疾患または炎症疾患の予防または治療用薬学組成物。
- ビフィドバクテリウム・ロンガムIM55(Bifidobacterium longum IM55)KCCM11961P、ラクトバチルス・プランタルムIM76(Lactobacillus plantarum IM76)KCCM11962Pまたはその混合物を個体に投与することを含む、アレルギー疾患の予防または治療方法。
- アレルギー疾患の予防または治療のためのビフィドバクテリウム・ロンガムIM55(Bifidobacterium longum IM55)KCCM11961P、ラクトバチルス・プランタルムIM76(Lactobacillus plantarum IM76)KCCM11962Pまたはその混合物の用途。
- アレルギー疾患の予防または治療のための薬剤を生産するためのビフィドバクテリウム・ロンガムIM55(Bifidobacterium longum IM55)KCCM11961P、ラクトバチルス・プランタルムIM76(Lactobacillus plantarum IM76)KCCM11962Pまたはその混合物の用途。
- アレルギー疾患の予防または治療に用いるためのビフィドバクテリウム・ロンガムIM55(Bifidobacterium longum IM55)KCCM11961P、ラクトバチルス・プランタルムIM76(Lactobacillus plantarum IM76)KCCM11962Pまたはその混合物を含む組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20170013632 | 2017-01-31 | ||
KR10-2017-0013632 | 2017-01-31 | ||
PCT/KR2018/001359 WO2018143678A1 (ko) | 2017-01-31 | 2018-01-31 | 신규 유산균 및 이의 용도 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021020363A Division JP7124142B2 (ja) | 2017-01-31 | 2021-02-12 | 新規乳酸菌およびその用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2020515240A true JP2020515240A (ja) | 2020-05-28 |
JP6839298B2 JP6839298B2 (ja) | 2021-03-03 |
Family
ID=63040871
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019541313A Active JP6839298B2 (ja) | 2017-01-31 | 2018-01-31 | 新規乳酸菌およびその用途 |
JP2021020363A Active JP7124142B2 (ja) | 2017-01-31 | 2021-02-12 | 新規乳酸菌およびその用途 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021020363A Active JP7124142B2 (ja) | 2017-01-31 | 2021-02-12 | 新規乳酸菌およびその用途 |
Country Status (11)
Country | Link |
---|---|
US (2) | US11660321B2 (ja) |
JP (2) | JP6839298B2 (ja) |
KR (2) | KR101999259B1 (ja) |
CN (2) | CN116676222A (ja) |
AU (2) | AU2018216532B2 (ja) |
BR (1) | BR112019015806A2 (ja) |
CA (2) | CA3178100A1 (ja) |
MX (2) | MX2019009079A (ja) |
RU (1) | RU2752157C2 (ja) |
SG (3) | SG10202107425VA (ja) |
WO (1) | WO2018143678A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2022003023A (ja) * | 2020-06-23 | 2022-01-11 | カゴメ株式会社 | アレルギー性鼻炎症状改善用組成物、アレルギー性鼻炎症状に起因するqol低下改善用組成物、及び、アレルギー性鼻炎症状に起因するくしゃみ抑制用組成物 |
WO2022050302A1 (ja) * | 2020-09-02 | 2022-03-10 | 日清食品ホールディングス株式会社 | Il-17の産生を抑制するビフィズス菌 |
WO2022131192A1 (ja) * | 2020-12-16 | 2022-06-23 | 株式会社明治 | 脳組織の炎症改善用組成物 |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7015674B2 (ja) * | 2017-10-27 | 2022-02-15 | 日清食品ホールディングス株式会社 | 制御性t細胞の分化誘導剤及び分化誘導方法 |
CN109498660A (zh) * | 2018-11-23 | 2019-03-22 | 江南大学 | 一种能够缓解特应性皮炎的植物乳杆菌ccfm8610的应用 |
KR102074445B1 (ko) * | 2018-12-12 | 2020-02-06 | 주식회사 비피도 | 류마티스관절염 개선, 예방 또는 치료를 위한 비피도박테리움 롱검 rapo 균주 및 이를 포함하는 조성물 |
CN109652349B (zh) * | 2019-02-25 | 2021-03-02 | 江南大学 | 一株能够缓解特应性皮炎的长双歧杆菌及其应用 |
WO2021040335A1 (ko) * | 2019-08-23 | 2021-03-04 | 연세대학교 산학협력단 | 활성산소 조건에서 저항능을 가진 신규한 공생 미생물 균주 및 이의 용도 |
KR102254310B1 (ko) * | 2019-10-02 | 2021-05-21 | 주식회사 고바이오랩 | 락토바실러스 애시도필러스 kbl409 균주 및 그 용도 |
KR102263698B1 (ko) * | 2019-11-29 | 2021-06-09 | 롯데칠성음료주식회사 | 아토피 피부염 완화 또는 개선 효과를 가지는 락토바실러스 플랜타럼 lrcc5195 균주 및 이소말토올리고당 복합체 |
CN110960562B (zh) * | 2019-12-31 | 2020-10-16 | 广州市爱百伊生物技术有限公司 | 抗敏作用的益生菌组合物 |
JP6995411B2 (ja) * | 2020-02-18 | 2022-02-21 | AuB株式会社 | 新規ビフィドバクテリウム属細菌及びそれを含む組成物 |
CN111419883B (zh) * | 2020-03-13 | 2023-08-04 | 广州柏芳生物科技有限公司 | 一种治疗过敏性鼻炎的鼻腔喷剂的制备方法 |
KR102162470B1 (ko) | 2020-03-19 | 2020-10-06 | 주식회사 비피도 | 비피도박테리움 슈도카테눌라튬 c-rapo (kctc13986bp), 비피도박테리움 비피덤 att (kctc13474bp) 균주를 포함하는 쇼그렌증후군 억제용 식품 조성물 및 약학 조성물 |
CN111647526B (zh) * | 2020-05-18 | 2022-08-05 | 深圳华大基因农业控股有限公司 | 植物乳杆菌sd-h9、其益生菌菌剂及其应用 |
KR102154255B1 (ko) * | 2020-05-22 | 2020-09-09 | (주)녹십자웰빙 | 유산균을 함유하는 미세먼지 자극에 의한 호흡기 질환 또는 염증 질환 치료용 조성물 |
KR20220069248A (ko) * | 2020-11-20 | 2022-05-27 | 가톨릭대학교 산학협력단 | 비피도박테리움 속을 유효성분으로 포함하는 피부경화증에 대한 테라그노시스용 조성물 |
WO2022171654A1 (en) * | 2021-02-09 | 2022-08-18 | Lactobio A/S | Method for treating atopic disorders |
KR102268125B1 (ko) * | 2021-02-09 | 2021-06-22 | 주식회사 락토메이슨 | 한국인 영유아 유래 신규한 비피도박테리움 롱검 lm1024 균주, 및 상기 균주 또는 이의 배양물을 포함하는 월경전 증후군 완화용 조성물 |
KR102294442B1 (ko) | 2021-02-17 | 2021-08-27 | 주식회사 메디오젠 | 영유아 유래 유산균 락토바실러스 플란타럼 mg4555 및 이를 포함하는 장 건강 증진, 항산화 및 항비만용 조성물 |
KR102294437B1 (ko) | 2021-02-17 | 2021-08-27 | 주식회사 메디오젠 | 영유아 유래 유산균 락토바실러스 플란타럼 mg4553 및 이를 포함하는 장 건강 증진, 항산화 및 항비만용 조성물 |
KR102360233B1 (ko) * | 2021-03-26 | 2022-02-09 | (주)바이오일레븐 | 구강질환 예방 또는 개선 효과를 가지는 락토바실러스 퍼멘텀 균주 및 이의 용도 |
KR102445903B1 (ko) * | 2021-07-06 | 2022-09-22 | 롯데제과 주식회사 | 혈당 상승 저해 및 스트레스 조절 효과가 우수한 열처리된 락토바실러스 플랜타럼 lrcc5314 균주 및 용도 |
CN115466689B (zh) * | 2022-02-09 | 2023-06-16 | 中国科学技术大学 | 用于预防和/或治疗代谢类疾病的益生菌组合物及其应用 |
CN115181698B (zh) * | 2022-06-28 | 2023-09-08 | 广东粤港澳大湾区国家纳米科技创新研究院 | 一种益生菌组合物及应用 |
CN115364127A (zh) * | 2022-07-06 | 2022-11-22 | 华南理工大学 | 一种对免疫抑制小鼠具有调节作用的植物乳杆菌与益生元复合物 |
KR102568093B1 (ko) * | 2023-02-07 | 2023-08-22 | 주식회사 바이오뱅크힐링 | 비피도박테리움 롱검을 유효성분으로 포함하는 알레르기 질환의 예방 또는 치료용 조성물 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006273852A (ja) * | 2005-03-03 | 2006-10-12 | Meiji Milk Prod Co Ltd | ビフィズス菌を有効成分とするアレルギー予防および/または治療剤 |
KR20080075971A (ko) * | 2007-02-14 | 2008-08-20 | (주)네오팜 | 프로바이오틱스 복합 제제 |
JP2010522552A (ja) * | 2007-03-28 | 2010-07-08 | アリメンタリー・ヘルス・リミテッド | プロバイオティック性のビフィドバクテリウム菌株 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ID29150A (id) * | 1999-01-15 | 2001-08-02 | Entpr Ireland Cs | Penggunaan lactobacillus salivarius |
KR20050076374A (ko) | 2004-01-20 | 2005-07-26 | 김수남 | 아토피와 항알러지 및 장내유해세균의 암모니아 생산을저해하는 활성을 갖는 두류 유산균 발효물을 함유한기능성 제품 및 그의 제조방법 |
BRPI0616962B8 (pt) | 2005-10-06 | 2021-05-25 | Probi Ab | uso de lactobacillus para o tratamento de doenças autoimunes |
KR100715730B1 (ko) | 2005-11-15 | 2007-05-08 | 연세대학교 산학협력단 | 유해 병원성 미생물에 대한 항균활성을 갖는 신규비피도박테리움 롱검 a24 |
ES2381211T3 (es) | 2006-02-15 | 2012-05-24 | Nestec S.A. | Uso del Bifidobacterium longum para prevenir y tratar inflamaciones |
DK2203551T3 (da) * | 2007-10-20 | 2013-10-28 | Univ Liege | Bifidobakterieart |
CN104784694A (zh) * | 2009-06-19 | 2015-07-22 | 杜邦营养生物科学有限公司 | 治疗糖尿病及相关病症的双歧杆菌 |
KR101178217B1 (ko) * | 2009-10-28 | 2012-09-07 | 씨제이제일제당 (주) | 신규한 락토바실러스 플란타룸 및 이를 포함하는 조성물 |
EP2498789B1 (en) * | 2009-11-11 | 2016-06-22 | Alimentary Health Limited | Probiotic bifidobacterium strain |
UA109123C2 (uk) | 2010-01-28 | 2015-07-27 | Пробіотична композиція для застосування в лікуванні запалення кишечнику | |
JP4942831B2 (ja) | 2010-03-19 | 2012-05-30 | 株式会社キティー | 抗アレルギー用組成物 |
EP2868206B1 (en) | 2012-07-05 | 2016-09-14 | Centro Nacional De Tecnología Y Seguridad Alimentaria, Laboratorio Del Ebro | Microparticles for the encapsulation of probiotics, preparation and uses thereof |
KR101740583B1 (ko) * | 2014-02-17 | 2017-05-29 | 경희대학교 산학협력단 | 비만 억제 효능을 갖는 신규 유산균 및 이의 용도 |
US9587284B2 (en) * | 2014-02-21 | 2017-03-07 | Asian Probiotics and Prebiotics Ltd. | Lactic acid bacterium having immunomodulatory and anti-allergic effects and pharmaceutical composition containing the same |
KR20160069733A (ko) | 2014-12-09 | 2016-06-17 | (주)바이오리듬 | 신규한 균주로 알러지, 아토피성 피부염, 비염, 가려움증 등의 개선치료 및 면역력조절 기능을 갖는 Lactobacillus plantarum K-1 BR 균주 |
JP2016136890A (ja) | 2015-01-28 | 2016-08-04 | 株式会社ヤクルト本社 | 乳酸菌のインターロイキン10産生誘導能の増強方法 |
KR20170032815A (ko) * | 2015-09-15 | 2017-03-23 | 경희대학교 산학협력단 | 신규 유산균 및 퇴행성 뇌질환 또는 인지기능의 예방, 개선 또는 치료용 조성물 |
KR101655778B1 (ko) | 2016-02-19 | 2016-09-09 | 대한민국 | 락토바실러스 플란타룸 k46 및 이를 포함하는 조성물 |
KR101750468B1 (ko) | 2016-03-04 | 2017-06-27 | 주식회사 메디오젠 | 락토바실러스 퍼멘툼 mg901 또는 락토바실러스 플란타룸 mg989를 포함하는 조성물 |
KR101743044B1 (ko) | 2016-06-28 | 2017-06-02 | 바이오제닉스코리아 주식회사 | 면역증진 및 장내환경개선용 건강기능성 식품 |
-
2018
- 2018-01-31 CA CA3178100A patent/CA3178100A1/en active Pending
- 2018-01-31 US US16/481,643 patent/US11660321B2/en active Active
- 2018-01-31 SG SG10202107425VA patent/SG10202107425VA/en unknown
- 2018-01-31 JP JP2019541313A patent/JP6839298B2/ja active Active
- 2018-01-31 KR KR1020180012186A patent/KR101999259B1/ko active Application Filing
- 2018-01-31 BR BR112019015806-5A patent/BR112019015806A2/pt unknown
- 2018-01-31 CA CA3052134A patent/CA3052134C/en active Active
- 2018-01-31 RU RU2019127021A patent/RU2752157C2/ru active
- 2018-01-31 WO PCT/KR2018/001359 patent/WO2018143678A1/ko unknown
- 2018-01-31 AU AU2018216532A patent/AU2018216532B2/en active Active
- 2018-01-31 CN CN202310634964.0A patent/CN116676222A/zh active Pending
- 2018-01-31 MX MX2019009079A patent/MX2019009079A/es unknown
- 2018-01-31 CN CN201880009638.8A patent/CN110494551B/zh active Active
- 2018-01-31 SG SG11201907043VA patent/SG11201907043VA/en unknown
- 2018-01-31 SG SG10201913050RA patent/SG10201913050RA/en unknown
-
2019
- 2019-07-04 KR KR1020190080934A patent/KR102036841B1/ko active IP Right Grant
- 2019-07-31 MX MX2023003416A patent/MX2023003416A/es unknown
-
2021
- 2021-02-12 JP JP2021020363A patent/JP7124142B2/ja active Active
- 2021-07-15 AU AU2021205078A patent/AU2021205078B2/en active Active
-
2023
- 2023-04-21 US US18/137,541 patent/US20230355690A1/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006273852A (ja) * | 2005-03-03 | 2006-10-12 | Meiji Milk Prod Co Ltd | ビフィズス菌を有効成分とするアレルギー予防および/または治療剤 |
KR20080075971A (ko) * | 2007-02-14 | 2008-08-20 | (주)네오팜 | 프로바이오틱스 복합 제제 |
JP2010522552A (ja) * | 2007-03-28 | 2010-07-08 | アリメンタリー・ヘルス・リミテッド | プロバイオティック性のビフィドバクテリウム菌株 |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2022003023A (ja) * | 2020-06-23 | 2022-01-11 | カゴメ株式会社 | アレルギー性鼻炎症状改善用組成物、アレルギー性鼻炎症状に起因するqol低下改善用組成物、及び、アレルギー性鼻炎症状に起因するくしゃみ抑制用組成物 |
JP7143044B2 (ja) | 2020-06-23 | 2022-09-28 | カゴメ株式会社 | アレルギー性鼻炎症状改善用組成物、アレルギー性鼻炎症状に起因するqol低下改善用組成物、及び、アレルギー性鼻炎症状に起因するくしゃみ抑制用組成物 |
WO2022050302A1 (ja) * | 2020-09-02 | 2022-03-10 | 日清食品ホールディングス株式会社 | Il-17の産生を抑制するビフィズス菌 |
WO2022131192A1 (ja) * | 2020-12-16 | 2022-06-23 | 株式会社明治 | 脳組織の炎症改善用組成物 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6839298B2 (ja) | 新規乳酸菌およびその用途 | |
KR101889281B1 (ko) | 다양한 기능성을 가진 신규 유산균 및 이의 용도 | |
AU2019216129B2 (en) | Lactobacillus plantarum KBL396 strain and use thereof | |
KR100908254B1 (ko) | 항알레르기용 조성물 | |
JP2021522867A (ja) | ラクトバチルス・パラカゼイ株及びその使用 | |
KR101937364B1 (ko) | 면역조절 작용을 가는 사람 소화관 유래 신규 유산균 및 이의 용도 | |
KR101511976B1 (ko) | 면역증강 활성을 가지는 신규한 락토바실러스 퍼멘텀 hy7301 및 이를 유효성분으로 함유하는 제품 | |
KR102224072B1 (ko) | 면역 조절능력과 혈중콜레스테롤 감소 능력이 모두 뛰어난 비피도박테리엄 롱검 아종 균주 및 이의 용도 | |
JP2020022488A (ja) | 多様な機能性を有する新規乳酸菌およびその用途 | |
TW201609120A (zh) | 含乳酸菌之腸道屏障功能促進劑 | |
EP3793580A1 (en) | Probiotic strain lactobacillus kefiri sgl 13 and use thereof for the prevention and treatment of intestinal inflammation and in the prevention of intestinal neoplasms | |
EP3578637A1 (en) | Novel lactic acid bacteria and use thereof | |
RU2790442C2 (ru) | Новый штамм lactobacillus plantarum, композиции, содержащие его, и связанный с ним способ и его применение | |
KR100854816B1 (ko) | 항알레르기용 조성물 | |
TW202417026A (zh) | 益生菌組合及其用於腸胃道保健或提升免疫力的用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20190731 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190730 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200728 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201028 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210119 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210212 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6839298 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |